Google babble translated, see link for charts, etc.:
Approved the first vaccine against dengue
About 40% of the world's population is at risk of contracting dengue
DENGUE| 09 DIC 2015 1:58 PM |EFE
MEXICO. Health authorities in Mexico today authorized the first vaccine against dengue in the world after evidence of their quality, safety and therapeutic efficacy in a global protocol in which more than 40,000 patients participated.
The Health Ministry said in a statement that the vaccine was approved after a process of analysis of more than two years contemplated an exchange of information with leading experts in the field at national and international level.
The vaccine, developed by Sanofi Pasteur and whose approval by the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) makes Mexico "to regulatory vanguard" is indicated for people aged 9 to 45 who live in areas where Dengue is endemic.
It works for all four serotypes of the virus causing the disease "has an average efficiency of 60.5% for the prevention of dengue and 93.2% for the prevention of severe dengue".
According to the World Health Organization (WHO), about 40% of the world's population is at risk of contracting dengue, which equals 3,900 million.
"An estimated 400 million are infected each year in more than 128 countries around the world." In Mexico, last year 32,100 cases were registered, of which 23,432 correspond to non-severe dengue and 8,668 to severe dengue, "explained the Ministry of Health.
The social cost associated with dengue, he said, exceeded 3,200 million pesos (about 188 million dollars) in 2014, equivalent to 2.5% of the budget allocated to the whole health sector in Mexico for 2016.
The vaccine can you prevent more than 8,000 hospitalizations in Mexico, 104 deaths annually and generate savings to public finances by 1,100 million pesos (65 million dollars) a year by the reduction in costs associated with medical care, estimated.
"An estimated 400 million are infected each year in more than 128 countries around the world." In Mexico, last year 32,100 cases were registered, of which 23,432 correspond to non-severe dengue and 8,668 to severe dengue, "explained the Ministry of Health.
Cofepris asked the French drug plan risk management designed especially for Mexico, including an electronic record of the vaccinated population and reporting of adverse reactions "through medical centers sentries located in endemic populations in which it is applied ".
"Historic milestone"
The CEO of Sanofi Pasteur, Olivier Brandicourt, held the first authorization of the vaccine, calling it a "historic milestone" for the company, the public health "and more importantly, for half the world's population living at risk of suffering from dengue. "
The approval comes after an extensive clinical development program in which more than 40,000 people from 15 countries participated, including several in Latin America.
Mexico is with the Philippines the only nation in the world that participated in the three stages of clinical trials of a decade that began in 2004.
The company announced in a statement that production of the vaccine against dengue already begun in France, so the first doses are available.
He noted that the regulatory review process for the vaccine against dengue continues in other endemic countries and reiterated its commitment to launch the first vaccine in those countries where dengue is a major public health priority.
The dengue virus is transmitted by the mosquito "Aedes aegypti" and symptoms of the disease include high fever, headache, muscle and joint pain, vomiting, sore eyes and a characteristic rash.
People infected annually, two million, mostly children, develop the hemorrhagic variety, which can be fatal.
It occurs mostly in tropical and subtropical climates of the planet, both in urban and suburban areas, and the direct and indirect cost estimate is 9,000 dengue billion a year globally.
http://www.diariolibre.com/noticias/salud/aprueban-la-primera-vacuna-contra-el-dengue-KF2124509
Approved the first vaccine against dengue
About 40% of the world's population is at risk of contracting dengue
DENGUE| 09 DIC 2015 1:58 PM |EFE
MEXICO. Health authorities in Mexico today authorized the first vaccine against dengue in the world after evidence of their quality, safety and therapeutic efficacy in a global protocol in which more than 40,000 patients participated.
The Health Ministry said in a statement that the vaccine was approved after a process of analysis of more than two years contemplated an exchange of information with leading experts in the field at national and international level.
The vaccine, developed by Sanofi Pasteur and whose approval by the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) makes Mexico "to regulatory vanguard" is indicated for people aged 9 to 45 who live in areas where Dengue is endemic.
It works for all four serotypes of the virus causing the disease "has an average efficiency of 60.5% for the prevention of dengue and 93.2% for the prevention of severe dengue".
According to the World Health Organization (WHO), about 40% of the world's population is at risk of contracting dengue, which equals 3,900 million.
"An estimated 400 million are infected each year in more than 128 countries around the world." In Mexico, last year 32,100 cases were registered, of which 23,432 correspond to non-severe dengue and 8,668 to severe dengue, "explained the Ministry of Health.
The social cost associated with dengue, he said, exceeded 3,200 million pesos (about 188 million dollars) in 2014, equivalent to 2.5% of the budget allocated to the whole health sector in Mexico for 2016.
The vaccine can you prevent more than 8,000 hospitalizations in Mexico, 104 deaths annually and generate savings to public finances by 1,100 million pesos (65 million dollars) a year by the reduction in costs associated with medical care, estimated.
"An estimated 400 million are infected each year in more than 128 countries around the world." In Mexico, last year 32,100 cases were registered, of which 23,432 correspond to non-severe dengue and 8,668 to severe dengue, "explained the Ministry of Health.
Cofepris asked the French drug plan risk management designed especially for Mexico, including an electronic record of the vaccinated population and reporting of adverse reactions "through medical centers sentries located in endemic populations in which it is applied ".
"Historic milestone"
The CEO of Sanofi Pasteur, Olivier Brandicourt, held the first authorization of the vaccine, calling it a "historic milestone" for the company, the public health "and more importantly, for half the world's population living at risk of suffering from dengue. "
The approval comes after an extensive clinical development program in which more than 40,000 people from 15 countries participated, including several in Latin America.
Mexico is with the Philippines the only nation in the world that participated in the three stages of clinical trials of a decade that began in 2004.
The company announced in a statement that production of the vaccine against dengue already begun in France, so the first doses are available.
He noted that the regulatory review process for the vaccine against dengue continues in other endemic countries and reiterated its commitment to launch the first vaccine in those countries where dengue is a major public health priority.
The dengue virus is transmitted by the mosquito "Aedes aegypti" and symptoms of the disease include high fever, headache, muscle and joint pain, vomiting, sore eyes and a characteristic rash.
People infected annually, two million, mostly children, develop the hemorrhagic variety, which can be fatal.
It occurs mostly in tropical and subtropical climates of the planet, both in urban and suburban areas, and the direct and indirect cost estimate is 9,000 dengue billion a year globally.
http://www.diariolibre.com/noticias/salud/aprueban-la-primera-vacuna-contra-el-dengue-KF2124509